|本期目录/Table of Contents|

[1]王学文综述.癌肿和静脉血栓栓塞相关性研究进展[J].医学研究与战创伤救治(原医学研究生学报),2010,12(02):128-131.
点击复制

癌肿和静脉血栓栓塞相关性研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第12卷
期数:
2010年02期
页码:
128-131
栏目:
综述
出版日期:
2010-03-20

文章信息/Info

Title:
-
文章编号:
1672-271X(2010)02-0128-04
作者:
王学文综述
210002 江苏南京，南京军区南京总医院血液病科
Author(s):
-
关键词:
癌肿; 静脉血栓栓塞; 血栓形成; 危险因素
Keywords:
-
分类号:
R730.267；R364.15
DOI:
-
文献标志码:
A
摘要:
癌肿是最重要的获得性静脉血栓栓塞(VTE)的危险因素。癌肿可表达促凝蛋白，直接和间接地激活凝血系统，亦可产生炎性细胞因子，触发髙凝状态和血栓栓塞的危险。肿瘤包块可外压邻近血管而使静脉血流淤滞。还包括静止不动、癌肿及其治疗和潜在的易栓遗传因素等。许多常用的治疗措施亦增加VTE的危险，包括手术、化疗药物、辅助性激素的使用、应用血管生成抑制剂和留置中心静脉通道装置。某些确定的肿瘤类型发生VTE的危险较大。特发性血栓栓塞初次发病时需作广泛的肿瘤筛选，对发现潜在隐匿的恶性肿瘤具有早期诊断价值。
Abstract:
-

参考文献/References:

[1]Anderson FA Jr, Spencer FA. Risk factors for venous hromboembolism［J］.Circulation, 2003,107(23, suppl 1):I9-I16.
[2］Patel R, Cook DJ, Meade MO, et al. Burden of illness in venous thromboembolism in critical care: a multicenter observational study［J］.J Crit Care,2005,20(4):341-347.
[3］White RH. The epidemiology of venous thromboembolism［J］. Circulation,2003,107(23,suppl 1):I4-I8.
[4］Falanga A, Zacharski L. Deep vein thrombosis in cancer: the scale of the problem and approaches to management［J］.Ann Oncol,2005,16(5):696-701.
[5］Sorensen HT, Mellemkjaer L, Olsen JH, et al. Prognosis of cancers associated with venous thrombo-embolism［J］. N Engl J Med,2000,343(12):1846-1850.
[6］Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee［J］. Circulation,2009,119(3):480-486.
[7］Minino AM, Arias E, Kochanek KD, et al. Deaths:final data for 2000［J］. Natl Vital Stat Rep, 2002,50(1):1-119.
[8］Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community［J］. Thromb Haemost,2001,86(3):452-463.
[9］Caprini JA. Thrombosis risk assessment as a guide to quality patient care［J］. Dis Mon,2005,51(1):70-78.
[10］Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)［J］. Chest,2008,133 (suppl 6): S381-S453.
[11］ Lee AY, Levine MN. Venous thromboembolism and cancer: risks and outcomes［J］. Circulation,2003,107(23,suppl 1):I17-I21.
[12］Caine GJ, Stonelake PS, Lip GY, et al. The hypercoagulable state of malignancy: pathogenesis and current debate［J］. Neoplasia,2002,4(6):465-473.
[13］Oudega R, Moons KG, Karel Nieuwenhuis H, et al. Deep vein thrombosis in primary care: possible malignancy? ［J］. Br J Gen Pract,2006,56(530):693-696.
[14］Falanga A, Rickles FR. Management of thrombohemorrhagic syndromes (THS) in hematologic malignancies［M］. Hematology Am Soc Hematol Educ Program, 2007：165-171.
[15］Kamocka M, Rozalski M, Krajewska U, et al. Effect of cancer procoagulant (CP) on the growth and adhesion of MCF-7 cells to vitronectin in vitro［J］.Cancer Lett,2005,222(1):89-94.
[16］Goldenberg N, Kahn SR, Solymoss S. Markers of coagulation and angiogenesis in cancer-associated venous thromboembolism［J］. J Clin Oncol,2003,21(22):4194-4199.
[17］Zwicker JI, Furie BC, Furie B. Cancer-associated thrombosis［J］. Crit Rev Oncol Hematol,2007,62(2):126-136.
[18］Decousus H, Moulin N, Quenet S, et al. Thrombophilia and risk of venous thrombosis in patients with cancer［J］. Thromb Res,2007,120(suppl 2):S51-S61.
[19］Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer［J］. J Clin Oncol,2007,25(34):5490-5505.
[20］Rajkumar SV. Thalidomide therapy and deep venous thrombosis in multiple myeloma［J］. Mayo Clin Proc,2005,80(12):1549-1551.
[21］Lycette JL, Luoh SW, Beer TM, et al. Acute bilateral pulmonary emboli occurring while on adjuvant aromatase inhibitor therapy with anastrozole:case report and review of the literature［J］. Breast Cancer Res Treat,2006,99(2):249-255.
[22］Elice F, Jacoub J, Rickles FR, et al. Hemostatic complications of angiogenesis inhibitors in cancer patients［J］. Am J Hematol,2008,83(10):862- 870.
[23］van Heeckeren WJ, Sanborn SL, Narayan A, et al. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis［J］. Curr Opin Hematol,2007,14(5):468-480.
[24］Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia［J］. JAMA,2008,299(8):914-924.
[25］Stein PD, Beemath A, Meyers FA, et al. Incidence of venous thromboembolism in patients hospitalized with cancer［J］. Am J Med,2006,119(1):60-68.
[26］Carrier M, Le Gal G, Wells PS, et al. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?［J］. Ann Intern Med,2008,149(5):323-333.
[27］Piccioli A, Lensing AW, Prins MH, et al. Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial［J］. J Thromb Haemost,2004,2(6):884-889.

相似文献/References:

[1]潘 涛,张 均,范国峰,等.低分子肝素预防脑出血后静脉血栓的安全性研究[J].医学研究与战创伤救治(原医学研究生学报),2012,14(06):517.
　PAN Tao,ZHANG Jun,FAN Guo-feng,et al.Safety of low molecular weight heparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(02):517.

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2010-03-20